MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jjcc.2019.12.015

Медицинская библиотека · Journal of cardiology · 2020

Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients.

Kawaguchi Juri, Hamatani Yasuhiro, Hirayama Atsushi, Nishimura Kunihiro, Nakai Eri, Nakamura Emi, Miyata Michi, Kawano Yukie, Takada Yasuko, Anchi Yuta, Funabashi Sayaka, Kuroda Kensuke, Azechi Michiyo, Takahama Hiroyuki, Anzai Toshihisa, Yasuda Satoshi, Kitaoka Hiroaki, Izumi Chisato

СтатьяПеревод в очереди

Аннотация

BACKGROUND

In the field of palliative care, morphine is known to be effective for alleviating dyspnea in cancer patients. However, little is known regarding the safety and efficacy of morphine therapy for refractory dyspnea as palliative care in advanced heart failure (HF) patients.

METHODS

We retrospectively reviewed consecutive advanced HF patients who were referred to the Palliative Care Team at our institution and administered morphine for refractory dyspnea during hospitalization between September 2013 and December 2018. We investigated the details of morphine usage, vital signs, an 11-point quantitative symptom scale, and adverse events at baseline, 24 h, and 72 h after the start of treatment.

RESULTS

Morphine was administered for refractory dyspnea in 43 advanced HF patients [mean age: 73.5 years, male: 28 (65%), New York Heart Association functional class IV: 43 (100%), median left ventricular ejection fraction: 25%, median B-type natriuretic peptide level: 927 pg/ml, concurrent intravenous inotrope: 33 (77%)]. Median initial dose of morphine was 5 mg/day in both oral and intravenous administration and median duration of administration was 5 days. Significant decreases in an 11-point quantitative symptom scale [7 (5, 9) vs. 2 (1, 6); p <  0.01, (data available in 8 patients)] and respiratory rate (22.2 ± 6.1 vs. 19.7 ± 5.2 breaths per minute; p < 0.01) were observed 24 h after the start of morphine administration. Meanwhile, oxygen saturation, blood pressure, and heart rate were not significantly altered after treatment (NS). Common adverse events were delirium (18%) and constipation (8%); however, no lethal adverse event definitely related to morphine therapy occurred during treatment.

CONCLUSIONS

This single-center retrospective study revealed the clinical practice of morphine therapy and suggested that morphine therapy might be feasible for refractory dyspnea as palliative care in advanced HF patients.

Для цитирования: Kawaguchi Juri, Hamatani Yasuhiro, Hirayama Atsushi, Nishimura Kunihiro, Nakai Eri, Nakamura Emi, Miyata Michi, Kawano Yukie, Takada Yasuko, Anchi Yuta, Funabashi Sayaka, Kuroda Kensuke, Azechi Michiyo, Takahama Hiroyuki, Anzai Toshihisa, Yasuda Satoshi, Kitaoka Hiroaki, Izumi Chisato. Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients.. Journal of cardiology. 2020. DOI: 10.1016/j.jjcc.2019.12.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.